Date	Event Title	Add to Calendar
14 Dec	Closing of the acquisition of Deep Longevity, Inc	N/A
14 Dec	Announcement on the marketing authorisation approval granted to Orient EuroPharma Co., Ltd. from the Taiwan Food and Drug Administration in respect of Fortacin™	N/A
09 Dec	Extraordinary General Meeting
02 Dec	Announcement on the approval granted to Wanbang Pharmaceutical Marketing and Distribution Co., Ltd. from the National Medical Products Administration of China to submit the investigational new drug application in respect of Senstend™ for human clinical trial of a Licensed Product	N/A
02 Sep	Two share purchase agreements entered into with various sellers in respect of the acquisition of Deep Longevity, Inc., subject to the shareholders' approval to be sought at an extraordinary general meeting for a specific mandate for the issue and allotment of the consideration shares	N/A
27 Aug	Approval received from the European Commission for the switch of the marketing authorisation for Foratin™ to "Over-the-Counter" status from prescription	N/A
24 Aug	2020 Interim Results Announcement	N/A
17 Jun	2020 Annual General Meeting
31 Mar (As revised)	2019 Annual Results Announcement	N/A

Date

Event Title

Add to Calendar

14 Dec

Closing of the acquisition of Deep Longevity, Inc

N/A

14 Dec

Announcement on the marketing authorisation approval granted to Orient EuroPharma Co., Ltd. from the Taiwan Food and Drug Administration in respect of Fortacin™

N/A

09 Dec

Extraordinary General Meeting

02 Dec

Announcement on the approval granted to Wanbang Pharmaceutical Marketing and Distribution Co., Ltd. from the National Medical Products Administration of China to submit the investigational new drug application in respect of Senstend™ for human clinical trial of a Licensed Product

N/A

02 Sep

Two share purchase agreements entered into with various sellers in respect of the acquisition of Deep Longevity, Inc., subject to the shareholders' approval to be sought at an extraordinary general meeting for a specific mandate for the issue and allotment of the consideration shares

N/A

27 Aug

Approval received from the European Commission for the switch of the marketing authorisation for Foratin™ to "Over-the-Counter" status from prescription

N/A

24 Aug

2020 Interim Results Announcement

N/A

17 Jun

2020 Annual General Meeting

31 Mar
(As revised)

2019 Annual Results Announcement

N/A